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Abstract
The pregnane X receptor (PXR) was previously known as a xenobiotic receptor. Several recent studies suggested that PXR
also played an important role in lipid homeostasis but the underlying mechanism remains to be clearly defined. In this
study, we found that rifampicin, an agonist of human PXR, induced lipid accumulation in HepG2 cells. Lipid analysis showed
the total cholesterol level increased. However, the free cholesterol and triglyceride levels were not changed. Treatment of
HepG2 cells with rifampicin induced the expression of the free fatty acid transporter CD36 and ABCG1, as well as several
lipogenic enzymes, including stearoyl-CoA desaturase-1 (SCD1), long chain free fatty acid elongase (FAE), and lecithin-
cholesterol acyltransferase (LCAT), while the expression of acyl:cholesterol acetyltransferase(ACAT1) was not affected.
Moreover, in PXR over-expressing HepG2 cells (HepG2-PXR), the SCD1 expression was significantly higher than in HepG2-
Vector cells, even in the absence of rifampicin. Down-regulation of PXR by shRNA abolished the rifampicin-induced SCD1
gene expression in HepG2 cells. Promoter analysis showed that the human SCD1 gene promoter is activated by PXR and a
novel DR-7 type PXR response element (PXRE) response element was located at -338 bp of the SCD1 gene promoter. Taken
together, these results indicated that PXR activation promoted lipid synthesis in HepG2 cells and SCD1 is a novel PXR target
gene.
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Introduction
Lipid homeostasis is tightly maintained by balanced lipogenesis,
catabolism (b-oxidation), and uptake/secretion. Disruptions of
lipid formation and catabolism have been implicated in various
metabolic diseases, such as obesity and diabetes. Liver is a major
organ for lipogenesis, where most lipogenic genes, including the
fatty acid synthase (FAS), stearoyl-CoA desaturase-1 (SCD1) and
long chain free fatty acid elongase (FAE), are highly expressed.
Several nuclear receptors have been implicated in lipid homeo-
stasis, such as the liver X receptors (LXRs) [1], thyroid hormone
receptor (TR) [2] and peroxisome proliferator-activated receptors
(PPARs). Both LXRa and LXRb have been shown to promote
lipogenesis though direct and indirect mechanism [1,3,4]. Upon
activation, LXRs form a heterodimer with retinoid X receptor
(RXR) and bind to its direct target lipogenic genes promoter, such
as FAS, or up-regulate the sterol regulatory element binding
protein (SREBP)-1c, a transcriptional factor known to regulate the
expression of a battery of lipogenic enzymes [5,6,7]. TR can be
activated by thyroid hormone and subsequently increase tran-
scription of several genes involved in lipogenesis [8,9]. PPARs
have distinct roles in lipid metabolism. PPARa enhances the
metabolic usage of fatty acids by inducing enzymes involved in b-
oxidation [10,11]. PPARc is a key regulator of adipocyte
differentiation and promotes lipid storage in mature adipocytes
[12,13]. Overexpression of PPARc in liver of PPARa null mice
induced the expression of lipogenic genes, leading to hepatic
steatosis [14]. CD36, a membrane receptor capable of uptaking
modified forms of low-density lipoproteins (LDL) and fatty acids
from circulation [15,16], has been identified as a direct target of
PPARc in liver [17]. While expression of an activated form of
PPARd in the adipose tissues of transgenic mice was shown to
activate fat metabolism and produce lean mice that are resistant to
obesity induced either genetically or by a high fat diet [18].
The nuclear receptor pregnane X receptor (PXR; NR1I2),
originally isolated as a xenobiotic receptor, is highly expressed in
the liver, and plays a major role in drug metabolism and
elimination through its regulation of the expression of cytochrome
P450 enzymes [19]. Several recent studies suggested that PXR is
also involved in hepatic lipid homeostasis. Activation of PXR
perturbs lipid homeostasis in mice by decreasing b-oxidation,
increasing free acid uptake and lipogenesis, which results in
hepatic steatosis in mice [20,21,22,23]. Activation of PXR also
decreases the expression of carnitine palmitoyltransferase 1A
(CPT1A), which controls the entry of activated long-chain fatty
acids into the mitochondria, and mitochondrial 3-hydroxy-3-
methyl-glutarate-CoA synthase 2 (Hmgcs2), the rate-limiting
enzyme of ketogenesis. PXR regulates CPT1A and Hmgcs2
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expression through its crosstalk with the insulin-responsive fork-
head factor A2 (FoxA2) [21]. Another study showed that in VP-
hPXR transgenic mice, the expression of several genes involved in
fatty acid b-oxidation, such as PPARa and thiolase, was
suppressed [23]. The fatty acid translocase CD36 was established
as a direct target gene of PXR. PXR binds to a DR3 type PXRE
in the CD36 gene promoter and induces the expression of CD36,
increasing the fatty acid uptake in liver [23]. In human
hepatocytes (HHPC), PXR activation by rifampicin, a well-known
hPXR agonist, stimulates de novo lipogenesis through the activation
of S14, a small acidic protein that plays an important role in the
induction of lipogenic enzymes [20].
Stearoyl-CoA desaturase-1 (SCD1) is the rate-limiting enzyme
that converts palmitoyl- and stearoyl-coenzyme A to palmitoleoyl-
and oleoyl-coenzyme A, respectively [24]. The monounsaturated
products of SCD1 are preferred substrates for the synthesis of
triglycerides, cholesterol esters, and phospholipids [24]. The
expression of SCD1 is regulated by a number of dietary,
physiological and hormonal factors including insulin, fructose,
glucose, cholesterol and polyunsaturated fatty acids [25]. Activa-
tion of several nuclear receptors, such as LXRs [26], TR [27] and
PPARa [28], can induce SCD1 gene expression. SCD1 has been
reported as a direct target gene of LXRa and SREBP-1c [29]. In
mouse models, activation of PXR induced SCD1 gene expression
in the liver. However, whether SCD1 is up-regulated upon PXR
activation in human hepatocytes and whether the human SCD1 is
a direct PXR target gene are still unknown.
In this study, we showed that activation of PXR in the human
hepatoma HepG2 cells induced the expression of SCD1. We also
showed that SCD1 is a direct PXR target gene.
Materials and Methods
Reagents
Rifampicin, Oil Red O, Isopropanol, 49,6-diamidino-2-pheny-
lindole (DAPI), TO901317, penicillin and streptomycin were
purchased from Sigma (St. Louis, MO). Dimethyl sulfoxide
(DMSO) was purchased from Merck (Darmstadt, Germany).
Trizol, Dulbecco’s modified Eagle’s medium (DMEM) and fetal
bovine serum (FBS) were purchased from Gibco-BRL (Grand
Island, NY). BCA-100 protein quantitative analysis kit was from
Pierce (Rockford, IL). Rabbit polyclonal anti-PXR (H-160, sc-
25381), rabbit polyclonal anti-SCD1 (H-300, sc-30081), rabbit
anti-b-actin (sc-1618), goat anti-rabbit IgG-HRP (ZB-2308) were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Protein molecular weight markers were obtained from Pharmacia
(Saclay, France). Polyvinylidene Fluoride (PVDF) membrane for
western blotting was obtained from Millipore (Bedford, MA). All
other reagents and chemicals were of the highest purity grade
available.
Plasmids
pVP-PXR, pCYP3A4-Luc, pRL-tk and short hairpin RNA
(shRNA) construct against the hPXR were kindly provided by Dr.
Wen Xie (University of Pittsburg). pCMV-3Xflag was kindly
provided by Dr. Richard G. Pestell (Georgetown University). The
cDNA of human PXR was subcloned into pCMV-3Xflag between
HindIII and XbaI sites by PCR using the following pair of
oligonucleotides: forward primer, 59- ATTAAGCTTCTG-
GAGGTGAGACCCAAAGA-39, reverse primer: 59- ATTTC-
TAGATCAGCTACCTGTGATGCCGA-39. The pVP-PXR was
Figure 1. Rifampicin induced PXR nuclear translocation. HEK293T cells were transfected with pCMV-36flag-hPXR for 24 h, then treated with
rifampicin (Rif, 20 mM) for 2 h. PXR was detected using an anti-PXR polyclone antibody and FITC-tagged second antibody. Nucleuses were stained by
DAPI.
doi:10.1371/journal.pone.0067959.g001
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used as the PCR template. The different lengths of the 59-
regulatory sequences of human SCD1 gene were cloned by PCR.
The forward primers were: 59- GGAAGATCTATGG-
TAAGGCTCCTACAGACA-39 for SCD1-1039, 59- GGAA-
GATCTACGGTTTCCACAAAGAAGAT-39 for SCD1-653,
59- AATAGATCTGGGCAGAGCCATTGTTCG-39 for SCD1-
436 and 59- AATAGATCTCGAGGGTTCACCACTGTTT-39
for SCD1-267. The common reverse primer is 59- CCCAAGCT-
TAAATGCTAATGAGGCTTCTG-39. Genomic DNA isolated
from the HepG2 cells was used as the PCR template. The PCR
Figure 2. Rifampicin induced lipid accumulation in HepG2 cells. A. Oil red O staining of HepG2 cells. HepG2 cells were treated with
rifampicin 5 mM (A-3), 10 mM (A-4), 20 mM(A-5) or TO901317 (10 mM, A-2) for 48 h. Cells treated with DMSO (A-1) were used as control. B. The
stained lipid content was quantified by measuring absorbance at 510 nm. The triglyceride (TG, C), total cholesterol (TC, D) and free cholesterol (FC, E)
levels were measured. F. The ratio of TC/FC. All experiments were repeated at least three times. *, P,0.05.
doi:10.1371/journal.pone.0067959.g002
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products were cloned into the pGL3 vector between the BglII and
HindIII sites. Site-directed mutagenesis was performed by the
PCR overextension method [19]. All newly constructed plasmids,
as well as the site-directed mutagenesis, were confirmed by DNA
sequencing.
Cell Culture, PXR Stable Cell Line and PXR Knockdown
Experiments
HEK293T and HepG2 cells were obtained from the Institute &
Hospital Chinese Academy of Medical Sciences. Both cell lines
were maintained in DMEM supplemented with 10% FBS, 100
units/ml penicillin and 100 mg/ml streptomycin, and incubated
at 37uC in 5% CO2. To generate PXR stable cell line, pCMV-
3Xflag vector and pCMV-3Xflag-PXR were transfected into
HepG2 cells using Lipofectamine from Invitrogen (Carlsbad, CA,
USA) according to the manufacturer’s protocol. After 48 h
transfection, cells were subcultured (1:10) into 24-well-plate and
then selected by G418 (600 mg/ml) for 14 days. The cell colonies
were expanded and the expression of PXR was verified by RT-
PCR, western blot and immunostaining. The two stable cell lines
were named HepG2-Vector and HepG2-PXR, respectively. For
PXR RNA interference experiment, short hairpin RNA (shRNA)
constructs against the hPXR in the retroviral pRS backbone were
transfected into HepG2 cells using Lipofectamine 2000. Cells were
Figure 3. Genes expression analysis in HepG2 cells. HepG2 cells were treated with rifampicin at indicated concentrations for 48 h. Total RNA
was isolated and the selected lipid metabolism genes expression was determined by RT-PCR. A. Expression of CYP3A4, CD36 and ABCG1. B.
Expression of several lipogenic genes. C, The relative gene level was analyzed using ImageJ from at least three independent experiments. *, P,0.05;
**, P,0.01. D, Knockdown of PXR by shRNA abolished rifampicin-induced SCD1 gene expression in HepG2 cells. E. The SCD1 gene protein level in
HepG2 cells after incubation with rifampicin. The intensity of the bands was measured using ImageJ. *, P,0.05. F. The expression of LCAT and ACAT1
gene.
doi:10.1371/journal.pone.0067959.g003
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maintained in culture medium for 24 h before rifampicin
treatment.
Oil Red O Staining
HepG2 cells were seeded in 6-well plates and treated with
TO901317 or rifampicin for 48 h at indicated concentrations. For
Oil Red O staining, cells were washed three times with phosphate-
buffered saline (PBS) and fixed with 4% formaldehyde for 1 h. Oil
Red O (0.5% in isopropanol), diluted with water (3:2), filtered
twice with a 0.45 mm filter, and added to fixed cells for 15 min at
room temperature. Cells were washed with 70% ethanol and
water before being visualized by light microscopy and photo-
graphed. Then the stained lipid droplets were dissolved in
isopropanol and quantified by measuring the absorbance at
510 nm.
Lipid Profile Analysis
HepG2 cells were treated as described above. The triglyceride
and cholesterol levels of the cells were measured using triglyceride
assay kit and cholesterol assay kit purchased from Applygen
Technologies Inc (Beijing, China), respectively. The cell lysate
protein concentrations were measured using the BCA method.
RNA Isolation and Semi-quantitative RT-PCR
Total RNA was isolated using Trizol reagent (GIBCO-BRL).
RNA concentrations were determined using Gene Quant (Amer-
sham Pharmacia Biotech). 2 mg of total RNA were used to
synthesize the first strand cDNA. Relative genes expression was
determined by semi-quantitative RT-PCR using the Gene Amplify
PCR System. The amplification product electrophoresis was
carried out on 1.2% agarose gels, visualized by ethidium bromide
staining, and photographed. The bands intensity was analyzed
using ImageJ from at least three independent experiments. The
SCD1 gene mRNA level was confirmed by real-time RT-PCR.
Western Blot Analysis
Cells were harvested in cell lysis buffer (16PBS, 1% Nonidet P-
40, 0.5% sodium deoxycholate, and 0.1% SDS) containing freshly
added protease inhibitor cocktail from Sigma (St. Louis, MO).
20 mg total protein was used to load each well. Proteins were
electrophoretically transferred onto PVDF membranes and then
blocked in 5% non-fat milk in TBST. The blocked membranes
were incubated with anti-PXR, anti-SCD1 or anti-b-actin
antibodies (1:1000) overnight at 4uC and then with secondary
antibody (1:5000) for 2 h at RT. Blots were washed three times
with TBST and subsequently developed using the Pierce ECL kit.
Transient Transfections and Luciferase Activity Assay
HEK293T cells in 24-well plates were transiently transfected
with 1.25 mg of total DNA (expression plasmids for 900 ng of
PXR, 300 ng of luciferase reporter vector, and 50 ng of pRL-tk)
using SuperFect Transfection Reagent from Qiagen (Valencia,
CA). 12 h after transfection, cells were treated with rifampicin
(10 mM) or DMSO for 24 h. The firefly luciferase luminescence
was normalized with the renilla using the Dual luciferase assay
Figure 4. Establishment of the HepG2-PXR stable cell line. The selection methods of HepG2-PXR and HepG2-Vector cells were described in
Materials and Methods. A to D. The selected cells were verified for PXR expression using RT-PCR (A), western blot using an anti-PXR antibody (B) and
an anti-flag antibody (C), and immunofluorescence using an anti-PXR antibody (D). E. Dual-luciferase assay of transcriptional activity of PXR on
CYP3A4 in HepG2-Vector and HepG2-PXR cells. pCYP3A4-Luc and pRL-tk were transfected into these two cell types for 24 h, and then treated with
rifampicin (10 mM) for another 24 h. Three independent experiments were performed. *, P,0.05.
doi:10.1371/journal.pone.0067959.g004
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system (Promega). Transfection experiments were performed in
triplicate and repeated independently for at least three times.
Immunochemistry Staining
For HepG2-Vector and HepG2-PXR cells, cells seeded in 24-
well plates containing a glass cover slip were washed with 1X PBS
and then fixed with 4% neutral buffered formaldehyde solution for
20 min at RT. Cells were then treated with 0.1% Triton X-100 in
PBS for 10 min at RT. After being blocked with 1% BSA/PBS for
1 h at RT, cells were incubated with anti-PXR antibody (1:200 in
1% BSA/PBS) overnight at 4uC. After washing with PBS, FITC-
tagged goat-anti-rabbit IgG (1:200 in 1% BSA/PBS) were added
to the cells and incubated at RT for 40 min. Then the slides were
washed in PBS and mounted on mounting medium containing
DAPI. The results were visualized on a Zesis fluorescence
microscope. For HEK293T cells, pCMV-3Xflag-PXR were
transiently transfected cells in 24-well plates containing a glass
cover slip. After 24 h of transfection, cells were treated with
rifampicin (10 mM) or DMSO for 2 h. The subsequent procedures
were the same as described for the HepG2 cells.
Electrophoretic Mobility Shift Assay (EMSA)
PXR and RXR receptors proteins were prepared using the
TNT in vitro transcription and translation system (Promega). The
binding reactions were as previously described [30]. Protein-DNA
complex was resolved by electrophoresis through 5% polyacryl-
amide gel in 0.56TBE at 4uC for 1-3 h. For oligonucleotide
competition experiments, unlabeled oligonucleotides were added
to the reaction at 100-fold molar excess to the radio-labeled probe.
Figure 5. Most overexpressed PXR was located in the nucleus of HepG2-PXR cells. HepG2-PXR and HepG2-Vector cells were seeded in 24-
well plates contained a glass coverslips. Cells were then treated with rifampicin for 2 h. Immunofluorescence using an anti-PXR antibody was used to
determine the PXR localization. The nucleus was stained by DAPI.
doi:10.1371/journal.pone.0067959.g005
SCD1 Contributes to the Lipogenic Effect by PXR
PLOS ONE | www.plosone.org 6 July 2013 | Volume 8 | Issue 7 | e67959
Statistics
The intensity of bands in RT-PCR and western blot were
analyzed by ImageJ. All data were analyzed by comparing means
with one-way ANOVA method using SPSS (Chicago, IL, USA,
version 16.0). Data were shown as mean 6 SEM and P,0.05
denotes statistically significant difference.
Results
Rifampicin Induced PXR Translocation to the Nucleus
PXR, known as a xenobiotic receptor, is a ligand-dependent
nuclear receptor, which forms heterodimers with the nuclear
receptor retinoic X receptor (RXR) upon activation by its agonists
and subsequently induces its target genes expression. In this
experiment, PXR was transiently transfected into HEK293T cells.
Twenty-four hour after transfection, cells were incubated with
rifampicin or DMSO for another 2 h. Most of the transfected
PXR was located in the cytosol in the absence of ligand (Figure 1).
Upon rifampicin incubation, PXR translocated to the nucleus
(Figure 1).
Rifampicin Induced Lipid Accumulation in HepG2 Cells
Previous studies have shown that activation of PXR in mice
induced hepatic lipid accumulation and steatosis [23]. In order to
determine whether activation of the human PXR in human liver
cells has the same effect, we treated HepG2 cells with rifampicin.
Oil red O staining showed lipid accumulation in HepG2 cells after
rifampicin incubation (Figure 2A and Figure 2B). Lipid profile
analysis showed that the triglyceride level was not changed in the
cells (Figure 2C), whereas the total cholesterol level was
significantly increased (Figure 2D). However, the free cholesterol
level was not changed (Figure 2E), indicating that the cholesterol
ester level was induced in HepG2 cells after rifampicin treatment.
Rifampicin Affected the Expression of Genes that Impact
Lipid Homeostasis
The lipid accumulation in HepG2 cells prompted us to examine
the effect of rifampicin on the expression of genes that affect lipid
homeostasis. RT-PCR analyses showed that the expression of
CD36, a fatty acid translocase that is responsible for the high
affinity uptake of fatty acids, was up-regulated (Figure 3A). In
mouse models, CD36 has been established as a common target
gene of LXR, PXR and PPARc in promoting steatosis [31]. The
expression of ATP-binding cassette sub-family G member 1
(ABCG1), a gene involved in cholesterol and phospholipids
transport, was also increased (Figure 3A). The expression of
PPARc was not affected (Figure 3B), which was different from
the results from mice [23,30]. In addition, the expression of two
Figure 6. Genes expression in PXR-HepG2 cells. HepG2-PXR and HepG2-Vector cells were treated with rifampicin (10mM) or DMSO for 48 h. A.
Total RNA was isolated and the selected genes expression was determined by RT-PCR. B, The relative gene level was analyzed using ImageJ from at
least three independent experiments. *, P,0.05; **, P,0.01. C. The protein level of SCD1 in the two type of cells with or without rifampicin treatment
was determined by western blot. The bands intensity was measured using ImageJ. *, P,0.05.
doi:10.1371/journal.pone.0067959.g006
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Figure 7. SCD1 is a direct target gene of PXR. A. Predicted putative PXREs on the SCD1 gene promoter and luciferase report gene constructs. B.
The SCD1 promoter luciferase report genes and pRL-tk were co-transfected into HepG2 cells for 24 h, followed 24 h treatment with rifampicin (+Rif)
or DMSO (-Rif). The luciferase activities were measured. *, P,0.05. C. The SCD1 promoter luciferase report genes and pRL-tk were co-transfected with
SCD1 Contributes to the Lipogenic Effect by PXR
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lipogenic enzymes, stearoyl-CoA desaturase-1 (SCD1) and long
chain free fatty acid elongase (FAE) (Figure 3B), was induced.
The relative expression of several genes was analyzed using ImageJ
from at least three independent experiments (Figure 3C). The
protein level of SCD1 was also increased as shown by western blot
analysis (Figure 3D). Down-regulation of PXR by shRNA
abolished rifampicin-induced SCD1 gene expression in HepG2
cells (Figure 3E). The design and efficiency of PXR knockdown
by shRNA has previously been validated [32]. Interestingly, the
expression of lecithin-cholesterol acyltransferase (LCAT) was
increased (Figure 3F), which was consistent with the change of
cholesterol ester level in rifampicin-treated HepG2 cells. However,
the expression of ACAT1(acyl:cholesterol acetyltransferase), an
enzyme that catalyzes esterification of free cholesterol and fatty
acids in hepatocytes, was not affected by rifampicin in HepG2 cells
(Figure 3F). CYP3A4, a known PXR target gene, was induced as
expected (Figure 3A).
Establishment of PXR-overexpressing HepG2 Cells
Because of the low level of PXR expression in HepG2 cells, we
constructed HepG2-PXR cell line that stably overexpresses PXR
in order to better study the effect of PXR on lipogenesis. Human
PXR expression plasmid, pCMV-3Xflag-PXR, and control vector
plasmid, pCMV-3Xflag, were transfected into HepG2 cells, which
were then selected by G418 for 14 days. The cell colonies were
selected and expanded. The PXR and vector cell lines were
named HepG2-PXR and HepG2-Vector, respectively. The
expression of PXR at both mRNA and protein levels was verified.
RT-PCR analysis showed that the mRNA level of PXR in
HepG2-PXR cells was much higher than in HepG2-Vector cells
(Figure 4A). The PXR protein expression was confirmed by
western blot analysis using an anti-PXR antibody (Figure 4B) and
an anti-flag antibody (Figure 4C), and by immunofluorescence
using an anti-PXR antibody (Figure 4D). To functionally test the
stable cells, pCYP3A4-Luc was transfected into HepG2-PXR and
HepG2-Vector cells and the transfected cells were treated by
rifampicin. As expected, compared with HepG2-vector cells, the
transcriptional activity of PXR on the CYP3A4 promoter reporter
gene was significantly higher in HepG2-PXR cells after rifampicin
activation (Figure 4E). The basal reporter activity in HepG2-
PXR cells was also higher than HepG2-Vector cells (Figure 4E).
These results were consistent with the cellular localization of PXR
in HepG2-PXR cells. As shown in immunochemistry staining,
even in the absence of rifampicin, most PXR protein was located
in the nucleus (Figure 5), while in HepG2-Vector cells, PXR was
evenly distributed within the cells (Figure 5). Upon rifampicin
incubation, PXR translocated into the nucleus in both HepG2-
Vector and HepG2-PXR cells (Figure 5).
The Expression of SCD1 was Induced in HepG2-PXR Cells
We next examined the expression of genes involved in lipid
homeostasis in HepG2-PXR and HepG2-Vector cells with or
without rifampicin incubation. As expected, the expression of
CD36, ABCG1, FAE, SCD1, LCAT and CYP3A4 was increased
in both cell lines after rifampicin treatment (Figure 6A), which
was consistent with the results in the parent HepG2 cells.
Moreover, the expression of these genes in HepG2-PXR cells
was higher than in HepG2-Vector cells (Figure 6A). The relative
expression of several genes was analyzed using ImageJ(Figure 6B).
The protein level of SCD1 was also significantly induced upon
rifampicin treatment, which was determined by western blot
analysis (Figure 6C).
SCD1 was a Direct Transcriptional Target of PXR
Based on the results of previous studies which found that SCD1
was induced both in PCN treated mouse liver and hPXR
transgenic mouse liver, and our current results that SCD1 was
also up-regulated in rifampicin treated HepG2 cells and HepG2-
PXR cells, we hypothesized that SCD1 is a direct transcriptional
target of PXR. Inspection of the hSCD1 gene promoter revealed
several potential PXR response elements (PXREs) (Figure 7A).
SCD1 promoter report genes containing different lengths of SCD1
gene promoter were constructed (Figure 7A). Transient transfec-
tions and dual-luciferase reporter gene assays were used to
determine whether and which potential elements were necessary
and sufficient in mediating the PXR transactivation in HepG2
cells. As shown in Figure 7B, the luciferase report gene that
contained a fragment from -267 bp to -436 bp from the
transcription start site of SCD1 gene was activated by rifampicin.
The luciferase report gene was also activated by co-transfection
with a plasmid expressing VP-PXR, a constitutively activated
PXR (Figure 7C). These results indicated that a potential PXRE
might exist within this segment. There are two potential PXREs in
this region, one is a DR4 type (GCGTCCcccaAGCTCC) located
at -368 bp to -353 bp, and the other is a DR7 type
(CTGCCAcgtctccCTGCCA) located at -338 bp to -320 bp. We
next mutated these two sites and repeated transient transfections
and dual-luciferase reporter gene assays. As shown in Figure 7D,
when only the DR4 element was mutated, the luciferase report
gene remained activated by rifampicin. While the reporter activity
was abolished when the DR7 element was mutated, indicating that
the DR7 element was required in mediating the PXR transactiva-
tion. The binding of the PXR-RXR heterodimers to the DR7
element was confirmed by EMSA. As shown in Figure 7E, the
PXR-RXR heterodimers bound to DR7 efficiently. The binding
was specific because the binding can be efficiently competed away
by the unlabeled cold probe, but not by the unlabeled mutant
probe. The binding of PXR-RXR heterodimers to a DR3 type
PXRE from the rat Cyp3a23 gene [19]was included as a positive
control.
Discussion
In this study, we showed that rifampicin induced lipid
accumulation in HepG2 cells through the up-regulation of several
genes involved in hepatic lipid uptake and lipogenesis, such as the
free fatty acid transporter CD36 and lipogenic enzymes FAE and
SCD1. We also established SCD1 as a direct transcriptional target
of PXR.
PXR overexpression and activation in VP-hPXR transgenic
mice caused hepatic steatosis, which is characterized by a marked
accumulation of hepatic triglycerides [23]. This is a result from
combined effect of PXR activation on increased hepatic free fatty
acid uptake, lipogenesis and suppression of b-oxidation [23]. The
PXR-mediated lipogenesis in rodents is independent of SREBP-
1c, which is distinct from that mediated by LXR [7,33]. However,
pVP-PXR expression vector into HepG2 cells for 24 h, and then the luciferase activities were measured. **, P,0.01. D. Site-direct mutagenesis of DR4
and DR7 elements on SCD1 promoter and then the transcriptional activity of PXR was measured. *, P,0.05. E. The binding of the PXR-RXR
heterodimers to DR7 was confirmed by EMSA. The binding of PXR-RXR heterodimers to a DR3 type PXRE from the rat Cyp3a23 gene was included as
a positive control. The arrowhead indicates the shift bands.
doi:10.1371/journal.pone.0067959.g007
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the effect of PXR on lipogenesis in human liver cells has not been
reported. In the current study, although the triglyceride level in
HepG2 cells was not changed by rifampicin (Figure 2C), the total
cholesterol level was increased (Figure 2D), mainly due to the
increased cholesterol ester in HepG2 cells (Figure 2E and 2F).
Consistent with these observations, the expression of LCAT, an
enzyme that converts free cholesterol into cholesteryl ester, was
up-regulated by rifampicin, though the expression of ACAT1 was
not affected (Figure 3F and Figure 6A). It remains to be
determined whether LCAT is a direct target gene of PXR.
SCD1 is a d-9 desaturase and is the rate-limiting enzyme
responsible for converting palmitic (16:0) and stearic acid (18:0) to
palmitoleic (16:1) and oleic (18:1) acids, respectively [24]. SCD1
gene expression is altered by a remarkable number of nutrients,
hormones and environmental factors [24,25]. Several nuclear
receptors, such as LXRs [26], TR [27] and PPARa [28] were
involved in the regulation of SCD1. SCD1 expression is positively
regulated by LXR, either directly through the binding of LXR to
an LXR response element in the SCD1 gene promoter, or
indirectly through LXR-mediated activation of SREBP-1c tran-
scription [34,35,36]. Dietary carbohydrates can increase hepatic
SCD1 gene expression through both SREBP-1c-dependent and
independent mechanisms [37]. Activation of the cellular immune
response via toll-like receptor 2 also increases the transcription of
SCD1, potentially via the nuclear factor kB elements in the SCD1
gene promoter [38].
Our transcription factor binding sites screen on the human
SCD1 gene promoter indicated several potential PXR binding
elements (PXREs) in the 2000-bp region of upstream of the
transcription start site (Figure 7A). Our promoter analysis results
have provided evidence to support SCD1 as a direct transcrip-
tional target of PXR. Both pharmacological (Rifampicin) and
genetic (VP-PXR) activation of PXR were sufficient to induce
SCD1 expression (Figure 7B and 7C). A DR7 type element
(CTGCCAcgtctccCTGCCA) at the -338 bp to -320 bp of SCD1
promoter was identified as a PXRE, where PXR directly bound to
this element and activated SCD1 transcription upon activation.
To our knowledge, this is the first report that PXR can bind to a
DR7 type of PXRE. PXR has been reported to bind to DR4 type
(CYP3As [39] and S14 [20]), ER6 type (CYP3A4), and DR3 type
(CD36 [23]) of PXREs.
In summary, we showed that PXR activation in the human
hepatoma HepG2 cells induced lipid accumulation though up-
regulation of several hepatic lipogenic genes. The human SCD1
was identified to be a direct transcriptional target of PXR via a
novel DR7 type PXRE on the SCD1 gene promoter.
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